Yang Y-H, Zhang S, Cui J-F, Lu B, Dong X-H, Song X-Y, Liu Y-K, Zhu X-X, Hu R-M
Institute of Endocrinology and Diabetology, Department of Endocrinology, Huashan Hospital, Fudan University, Shanghai, China.
Diabet Med. 2007 Dec;24(12):1386-92. doi: 10.1111/j.1464-5491.2007.02312.x.
Microalbuminuria is the earliest clinical sign of diabetic nephropathy (DN). However, the multifactorial nature of DN supports the application of combined markers as a diagnostic tool. Thus, another screening approach, such as protein profiling, is required for accurate diagnosis. Surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) is a novel method for biomarker discovery. We aimed to use SELDI and bioinformatics to define and validate a DN-specific protein pattern in serum.
SELDI was used to obtain protein or polypeptide patterns from serum samples of 65 patients with DN and 65 non-DN subjects. From signatures of protein/polypeptide mass, a decision tree model was established for diagnosing the presence of DN. We estimated the proportion of correct classifications from the model by applying it to a masked group of 22 patients with DN and 28 non-DN subjects. The weak cationic exchange (CM10) ProteinChip arrays were performed on a ProteinChip PBS IIC reader.
The intensities of 22 detected peaks appeared up-regulated, whereas 24 peaks were down-regulated more than twofold (P < 0.01) in the DN group compared with the non-DN groups. The algorithm identified a diagnostic DN pattern of six protein/polypeptide masses. On masked assessment, prediction models based on these protein/polypeptides achieved a sensitivity of 90.9% and specificity of 89.3%.
These observations suggest that DN patients have a unique cluster of molecular components in serum, which are present in their SELDI profile. Identification and characterization of these molecular components will help in the understanding of the pathogenesis of DN. The serum protein signature, combined with a tree analysis pattern, may provide a novel clinical diagnostic approach for DN.
微量白蛋白尿是糖尿病肾病(DN)最早的临床症状。然而,DN的多因素性质支持将联合标志物作为诊断工具应用。因此,需要另一种筛查方法,如蛋白质谱分析,以进行准确诊断。表面增强激光解吸/电离飞行时间质谱(SELDI-TOF-MS)是一种发现生物标志物的新方法。我们旨在利用SELDI和生物信息学来定义和验证血清中DN特异性蛋白质模式。
使用SELDI从65例DN患者和65例非DN受试者的血清样本中获取蛋白质或多肽模式。根据蛋白质/多肽质量的特征,建立了诊断DN存在的决策树模型。通过将其应用于22例DN患者和28例非DN受试者的盲法分组,我们估计了该模型正确分类的比例。在ProteinChip PBS IIC阅读器上进行弱阳离子交换(CM10)蛋白质芯片阵列检测。
与非DN组相比,DN组中检测到的22个峰的强度上调,而24个峰下调超过两倍(P<0.01)。该算法识别出一种由六种蛋白质/多肽质量组成的DN诊断模式。在盲法评估中,基于这些蛋白质/多肽的预测模型灵敏度为90.9%,特异性为89.3%。
这些观察结果表明,DN患者血清中有一组独特的分子成分,存在于他们的SELDI图谱中。识别和表征这些分子成分将有助于理解DN的发病机制。血清蛋白质特征与树状分析模式相结合,可能为DN提供一种新的临床诊断方法。